opnMe by Boehringer Ingelheim

BRD7/BRD9 inhibitor

BI-7273

Boehringer Ingelheim

Table of contents

Summary

BI-7273 is a dual BRD7/BRD9 inhibitor (IC_{50}, BRD7 = 117 nM, IC_{50}, BRD9 = 19 nM) and shows excellent selectivity versus the BET family.

Chemical Structure



Figure 1: 2D structure of BI-7273, a dual inhibitor of BRD7 and BRD9



Figure 2: BI-7273, 3D conformation, as observed in complex with BRD9 by X-ray crystallography

Highlights

BI-7273 is a potent dual BRD7/BRD9 inhibitor. This compound binds with high affinity to BRD7 and BRD9 and shows excellent selectivity versus other BET family members. Its overall ADME profile is good, which makes BI-7273 a suitable tool for both *in vitro* and *in vivo* experiments. It has good oral bioavailability and has shown moderate to high absorptive permeability and moderate plasma clearances upon *i.v.* dosing.
BI-7273 was developed in collaboration with the Structural Genomics Consortium (SGC).

Target information

The mammalian switch/sucrose nonfermentable (SWI/SNF) complex is one of four mammalian chromatin remodeling complexes. Recurrent inactivating mutations in certain subunits of this complex have been identified in different cancers. Despite its known roles in tumor suppression, the mammalian SWI/SNF complex has recently received attention as a potential target for therapeutic inhibition[2].

The human bromodomain family encompasses 61 domains, found on 46 proteins and BRD9 and BRD7 proteins containing a single acetyl-lysine reader bromodomain are components of the chromatin remodeling SWI/SNF BAF complex. A recent study highlighted the role of another SWI/SNF subunit, BRD9, in leukemia growth. The BRD9 bromodomain (BD) was shown to be required for the proliferation of acute myeloid leukemia (AML) cells[3].



Figure 3: BRD9 with BI-7273, as observed by X-ray[1].

In vitro activity

PROBE NAME / NEGATIVE CONTROL	BI-7273	BI-6354
MW [Da, free base][a]	353.4	279.3
ITC(BRD9) (K_D) [nM][b]	15	n.a.
AlphaScreen(BRD9) (IC_{50}) [nM][b]	19	27192
AlphaScreen(BRD7) (IC_{50}) [nM][b]	117	81896
AlphaScreen(BRD4-BD1) (IC_{50}) [nM][b]	>100,000	>100,000

[a] For the salt form you will get, please refer to the label on the vial and for the molecular weight of the salt, please refer to the FAQs
[b] For detailed assay conditions see Ref. 1

In vitro DMPK and CMC parameters

PROBE NAME / NEGATIVE CONTROL	BI-7273	BI-6354
logD @ pH 11	2.5	0.6
Solubility @ pH 7 [µg/mL]	>86	>59
Caco-2 permeability AB @ pH 7.4 [*10^{-6} cm/s]	1.4	63
Caco-2 efflux ratio	26	0.7
Microsomal stability (human/mouse/rat) [% Q_H]	<24 / 56 / <23	<24 / n.a. / <23
Hepatocyte stability (human/mouse/rat) [% Q_H]	17 / 58 / 7	n.a. / n.a. / 23
Plasma Protein Binding (human/mouse/rat) [%]	31 / 44 / 33	n.a. / n.a. / 62.8
CYP 3A4 (IC_{50}) [µM]	>50	n.a.
CYP 2C8 (IC_{50}) [µM]	>50	n.a.
CYP 2C9 (IC_{50}) [µM]	>50	n.a.
CYP 2C19 (IC_{50}) [µM]	>50	n.a.
CYP 2D6 (IC_{50}) [µM]	>50	n.a.

In vivo DMPK parameters

BI-7273 showed moderate to high absorptive permeability and moderate *in vivo* plasma clearances upon *i.v.* dosing. BI-7273 displayed good oral bioavailability.

BI-7273	MOUSE
Clearance [% Q_H]	57[a]
Mean residence time after *i.v.* dose [L/kg]	0.5[a]
t_{max} [h]	1.7[b]
C_{max} [nM]	2,970[b]
F [%]	39[b]
V_{ss} [L/kg]	1.6[a]

[a] *i.v.* dose: 5 mg/kg
[b] *p.o.* dose: 20 mg/kg

In vivo pharmacology

No *in vivo* pharmacological studies have been performed with BI-7273.

Negative control

BI-6354 is available as an *in vitro* negative control. It shows only very weak potency on BRD9 and BRD7 and no potency on BRD4.



Figure 4: BI-6354 which serves as an in vitro negative control

Selectivity

BI-7273 was screened on 48 bromodomains and 31 kinases. Beside BRD9 (K_D = <1 nM) and BRD7 (KD = <1 nM) only CECR2 (88 nM) and FALZ (K_D = 850 nM) showed a K_D < 1 µM in the DiscoverX assay (48 bromodomains). BI-7273 showed a K_D of 187 nM in the CECR2 ITC assay, but no cellular effect at 1 µM in FRAP assay. From the 31 kinases only 3 kinases (ACVR1, TGFBR1, ACVR2B) showing an % inhibition of > 43% @10 µM, for which the measured IC_{50} values were all > 3.5 µM.

SELECTIVITY DATA AVAILABLE	BI-7273	BI-6354
SafetyScreen44™ with kind support of eurofins	Yes	Yes
Invitrogen®	Yes	No
DiscoverX®	Yes	No
Dundee	No	No

Co-crystal structure of the Boehringer Ingelheim probe compound and the target protein.

The X-ray crystal structure of target in complex with BI-9564 is available (PDB code: 5EU1)[1].

Reference molecule(s)

LP99[4], I-BRD9[5], 'compound 28'[6], BI-9564[1,7].

Supplementary data

Selectivity data can be downloaded free of charge from opnMe.

References

1. Martin L. J., Koegl M., Bader G., Cockcroft X.-L., Fedorov O., Fiegen D., Gerstberger T., Hofmann M. H., Hohmann A. F., Kessler D., Knapp S., Knesl P., Kornigg S., Müller S., Nar H., Rogers C., Rumpel K., Schaaf O., Steurer S., Tallant C., Vakoc C. R., Zeeb M., Zoephel A,, Pearson M., Boehmelt G., McConnell D. Structure-based design of an in vivo active selective BRD9 inhibitor *J. Med. Chem.* **2016**, *59*, 4462−4475. DOI:10.1021/acs.jmedchem.5b01865, PubMed.

2. Fedorov O., Castex J., Tallant C., Owen D. R., Martin S., Aldeghi M., Monteiro O., Filippakopoulos P., Picaud S., Trzupek J. D., Gerstenberger B. S., Bountra C., Willmann D., Wells C., Philpott M., Rogers C., Biggin P. C., Brennan P. E., Bunnage M. E., Schüle R., Günther T., Knapp S., Müller S. Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance *Sci. Adv.* **2015**, *10*, e1500723. DOI:10.1126/sciadv.1500723, PubMed.

3. Hohmann A. F., Martin L. J., Minder J. L., Roe J.-S., Shi J., Steurer S., Bader G., McConnell D., Pearson M., Gerstberger T., Gottschamel T., Thompson D., Suzuki Y., Koegl M., Vakoc C. R. Sensitivity and engineered resistance of myeloid leukemia cells to BRD 9 inhibition *Nat. Chem. Biol.* **2016**, *12*, 672–679. DOI:10.1038/nchembio.2115, PubMed.

4. Clark P. G. K., Vieira L. C. C., Tallant C., Fedorov O., Singleton D. C., Rogers C. M., Monteiro O. P., Bennett J. M., Baronio R., Müller S., Daniels D. L., Méndez J., Prof. Knapp S., Brennan P. E., Dixon D. J. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor *Angew. Chem. Int. Ed. Engl.* **2015,** *54*, 6217-21. DOI: 10.1002/anie.201501394, PubMed.

5. Theodoulou N. H., Bamborough P., Bannister A. J., Becher I., Bit R. A., Che K. H., Chung C.-W., Dittmann A., Drewes G., Drewry D. H., Gordon L., Grandi P., Leveridge M., Lindon M., Michon A.-M., Molnar J., Robson S. C., Tomkinson N. C. O., Kouzarides T., Prinjha R. K., Humphreys P. G. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition *J. Med. Chem.* **2016**, *59*, 1425–1439. DOI:10.1021/acs.jmedchem.5b00256, PubMed.

6. Hay D. A., Rogers C. M., Fedorov O., Tallant C., Martin S., Monteiro O. P., Müller S., Knapp S., Schofielda C. J., Brennan P. E. Design and synthesis of potent and selective inhibitors of BRD7 and BRD9 bromodomains *Med. Chem. Commun.* **2015**, *6*, 1381-1386.DOI:10.1039/C5MD00152H.

7. Karim R. M., Schönbrunn E. An Advanced Tool To Interrogate BRD9 *J. Med. Chem.* **2016**, *59*, 4459−4461. DOI:10.1021/acs.jmedchem.6b00550, PubMed.